Dyne Therapeutics has reported new data from Phase I/II studies in myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy that it believes can position each candidate for US accelerated approval with best-in-class potential, and analysts see as validating the Waltham, MA-based company’s platform for oligonucleotide therapeutic.
Key Takeaways
-
Dyne reported new data from ongoing Phase I/II trials of its oligonucleotide conjugate therapies in DM1 and DMD that it thinks offer best-in-class potential.
- ...
On 20 May, Dyne reported that DYNE-101, its oligonucleotide antibody-drug conjugate (ADC) therapy for DM1, demonstrated dose-dependent mean splicing correction which in theory can reduce toxic myotonic dystrophy protein kinase...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
